VA
INM icon

VR Adviser’s InMed Pharmaceuticals INM Stock Holding History

VR Adviser’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.7K Buy
+32,685
New +$36.1K ﹤0.01% 33

Other funds holding INM

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UFM
Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

VR Adviser's INM Position: Q2 2026 in Review

VR Adviser opened a new position in InMed Pharmaceuticals (INM) in Q2 2026: 32,685 shares worth $50.7K. The stake represents ﹤0.01% of the portfolio and ranks #33 among its holdings.

20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

  • VR Adviser held 32,685 shares of InMed Pharmaceuticals worth $50.7K as of Q2 2026.
  • InMed Pharmaceuticals was a new VR Adviser position in Q2 2026.
  • InMed Pharmaceuticals made up ﹤0.01% of VR Adviser's portfolio in Q2 2026, its #33 holding.
  • 20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.